dr. hutchings on the aim of the echelon-1 study in hodgkin lymphoma
Published 6 years ago • 83 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:59
dr. hutchings on subgroup analysis of echelon-1 in hodgkin lymphoma
-
1:58
dr. straus on the 3-year results of the echelon-1 study in hodgkin lymphoma
-
3:25
echelon-1 trial: significance in hodgkin lymphoma
-
2:59
dr. ramchandren on the north american results of the echelon-1 study in hodgkin lymphoma
-
8:27
martin hutchings, eha 2018 – echelon-1 trial and chemotherapy regimens in hodgkin’s lymphoma
-
5:06
5-year follow-up of echelon-1: brentuximab plus avd versus abvd in hodgkin lymphoma
-
1:39
dr. rizvi on the echelon-1 trial follow-up in hodgkin lymphoma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:54
martin hutchings, md, considers how the echelon-1 study could be practice changing
-
1:57
dr. kaplan on the phase iii echelon-1 trial in hodgkin lymphoma
-
0:50
research builds on positive echelon-1 study in hodgkin lymphoma
-
3:50
overview of echelon-1 study for hodgkin lymphoma
-
2:47
hodgkin lymphoma updates in the uk: echelon-1
-
2:29
patient selection based on the echelon-1 study in chl
-
4:52
phase iii echelon-1 study: updated results of brentuximab vedotin chemotherapy for untreated chl
-
3:08
results of echelon-1 study for hodgkin lymphoma
-
1:02
seven-year os analysis from echelon-1: brentuximab vedotin avd versus abvd in hodgkin lymphoma
-
2:00
a 10-year pfs simulation model based on the echelon-1 trial in hodgkin lymphoma
-
9:41
echelon-1 study of brentuximab vedotin as frontline therapy for hodgkin's lymphoma